Advertisement

Melanoma Mab Fab - Biotech, Pharma and Life Science Channel

09:57 EDT 22nd May 2013 | BioPortfolio

PubMed Articles [ 1681 Associated PubMed Articles listed on BioPortfolio]

Tumor lysis syndrome and malignant melanoma.

Tumor lysis syndrome (TLS) is an oncological emergency that results from massive cytolysis of malignant cells with a sudden release of their contents into the systemic circulation. TLS was rarely desc...

Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection.

The development of exosomes as delivery vehicles requires understanding how and where exogenously administered exosomes are distributed in vivo. In the present study, we designed a fusion protein cons...

Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms.

The majority of human melanoma cell lines secretes vascular endothelial growth factor-A (VEGF-A) and expresses its receptors VEGFR-1, VEGFR-2 and neuropilin-1 (NRP‑1), a co-receptor for VEGF-A that...

Clinical effects of stereotactic radiation surgery in patients with metastatic melanoma.

We examined the effectiveness of stereotactic radiation surgery (SRS) in 14 patients with brain metastasis in our hospital. The age of the patients ranged 45-85 years old (mean, 65). Brain metastasis...

An engineered nanoplatform for bimodal anticancer phototherapy with dual-color fluorescence detection of sensitizers.

A multifunctional nanoplatform with four-in-one photoresponsive functionalities has been achieved through the co-encapsulation of two chromo-fluorogenic components within biocompatible polymeric nanop...

Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions.

Melanoma is increasing in incidence and remains a major public health threat. Although the disease may be curable when identified early, advanced melanoma is characterized by widespread metastatic dis...

Association between non-steroidal anti-inflammatory drug use and melanoma risk: a meta-analysis of 13 studies.

PURPOSE: Results of the association between non-steroidal anti-inflammatory drugs (NSAIDs) and melanoma risk have been inconsistent. We performed a meta-analysis of relevant studies to investigate the...

Influence of reflected UV irradiance on occupational exposure from combinations of reflective wall surfaces.

Outdoor workers who occupationally spend large periods of time exposed to ultraviolet irradiance are at increased risk of developing certain types of non-melanoma skin cancer in addition to being pron...

Results of surgical excision and evaluation of factors associated with survival time in dogs with lingual neoplasia: 97 cases (1995-2008).

Objective-To describe the clinical characteristics, treatments, outcomes, and factors associated with survival time in a cohort of dogs with lingual neoplasia that underwent surgical excision. Design-...

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.

Metastatic melanoma is characterized by a poor response to chemotherapy. Furthermore, there is a lack of established predictive and prognostic markers. In this single institution study, we correlated...

News Articles [ 1278 Associated News Articles listed on BioPortfolio]

BRIEF-Oncolytics Biotech U.S.-listed shares jump 10.3 percent premarket

NEW YORK, May 22 (Reuters) - Oncolytics Biotech Inc : * Oncolytics Biotech U.S.-listed shares jump 10.3 percent to $3 in premarket after phase 2 metastatic melanoma trial results

Oncolytics Biotech Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial

CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metasta...

Study shows PDH enzyme plays a major role in regulation of oncogene-induced cellular senescence

An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence i...

Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial

CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastat...

The Risk To Light-Skinned People Of Sun Exposure Highlighted By Study Of Young Israelis

A new study conducted using extensive medical records of over one million Israeli adolescents before military service shows clearly how exposure to the Israeli sun of young, light-skinned children inc...

Risk Of Melanoma Increased By Inflammatory Bowel Disease

Patients with inflammatory bowel disease(IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent great...

Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research

New data from the National Health and Wellness Survey show the effects of non-adherence on outcomes of patients with leukemia, melanoma or non-small cell lung cancer. New York, NY (PRWEB) May 21, 2013...

New factor to control oncogene-induced senescence discovered

A new article describes the major role that Pyruvate dehydrogenase (PDH) —- an enzyme of cellular energy metabolism -— plays in the regulation of the cellular senescence induced by the oncogene BR...

IBD patients are at higher risk of melanoma, report researchers

Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent grea...

New factor to control oncogene-induced senescence

An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence i...

Events [0 Results]

None

Companies [ 20 Associated Companies listed on BioPortfolio]

Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells...

Suntegrity Skincare

After losing her Mother to melanoma skin cancer, which claims nearly 8,650 people each year, Founder Tricia Trimble recognized the importance of proper sun protection. More import...

Cascade Technologies Corp.

Cascade Technologies Corp., through its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI), is a development-stage medical imaging device company, applying its proprie...

Cascade Technologies Corporation

Cascade Technologies Corp., through its wholly owned subsidiary Spectral Molecular Imaging, Inc., is a development-stage, medical imaging device company, applying its proprietary...

AB Science SA

Founded in 2001, AB Science is a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), a new class of targete...

CollabRx

The mission of CollabRx is to save lives by using information technology (IT) to personalize cancer treatments and accelerate research. Our web-based applications and services pow...

AIM at Melanoma

AIM at Melanoma, founded in memory of Charlie Guild, who died of melanoma at the age of 26, is the largest international melanoma foundation focused on melanoma research, patient...

Polynoma, Inc.

Polynoma, Inc. is an oncology-focused biotechnology company based in San Diego, the United States of America. Polynoma’s lead product candidate is the therapeutic vaccine POL...

Polynoma LLC

Malignant melanoma is the most serious form of skin cancer. An estimated 200,000 new cases of melanoma are diagnosed annually around the world, with about 76,000 in the United Sta...

Plexxikon Inc.

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032,...

Clinical Trials [ 602 Associated Clinical Trials listed on BioPortfolio]

A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumbab Therapy in Patients With Advanced Metastatic Melanoma

This is an open-label, dose-escalation, non-randomized, phase I study in patients with histologically confirmed Stage III or IV melanoma and at least three metastatic cutaneous or subcutan...

Azacitidine and Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Interfe...

PS-341 With Oral Temozolomide in Patients With Advanced Refractory Solid Tumors or Melanoma

Patients are asked to participate in this research because they have been diagnosed as having cancer that is not curable by any standard means including surgery or radiation therapy or oth...

Pegylated Interferon-Alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

The purpose of this study is to evaluate the efficacy and safety of adjuvant treatment with pegylated interferon-α-2a (PEG-IFN) vs. 'low dose' interferon-α-2a in patients with malignant...

Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma

This is a study of a melanoma vaccine. Study participants will have melanoma that invaded deeply and spread to lymph nodes or another location. Although the participants' melanoma has be...

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

This study evaluates a cancer vaccine in melanoma patients who have resected melanoma but are at high risk for recurrence (stages IIB-III). This is a single arm, open label, pilot/phase I...

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

RATIONALE: An infusion of a patient's lymphocytes that have been treated in the laboratory to remove certain immune cells may be an effective treatment for melanoma. Drugs, such as cycloph...

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

The aim of the study is to compare the safety and effectiveness of a new drug called PI-88, when used in combination with an approved chemotherapy drug called dacarbazine, in the treatment...

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is st...

Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is stu...

Videos

None Available

Medical and Biotech [MESH] Definitions

Melanoma-specific Antigens

Cellular antigens that are specific for MELANOMA cells.

Gp100 Melanoma Antigen

A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.

Mart-1 Antigen

A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.

Iris Neoplasms

Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.

Hutchinson's Melanotic Freckle

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

Search BioPortfolio:
Advertisement
review and buy Melanoma Mab Fab market research data and corporate reports here

Channels Quicklinks

Advertisement